The Economic Value of Rebuilding Fisheries

The global demand for protein from seafood –- whether wild, caught or cultured, whether for direct consumption or as feed for livestock –- is high and projected to continue growing. However, the ocean's ability to meet this demand is uncertain due to either mismanagement or, in some cases, lack of management of marine fish stocks. Efforts to rebuild and recover the world's fisheries will benefit from an improved understanding of the long-term economic benefits of recovering collapsed stocks, the trajectory and duration of different rebuilding approaches, variation in the value and timing of recovery for fisheries with different economic, biological, and regulatory characteristics, including identifying which fisheries are likely to benefit most from recovery, and the benefits of avoiding collapse in the first place. These questions are addressed in this paper using a dynamic bioeconomic optimisation model that explicitly accounts for economics, management, and ecology of size-structured exploited fish populations. Within this model framework, different management options (effort controls on small-, medium-, and large-sized fish) including management that optimises economic returns over a specified planning horizon are simulated and the consequences compared. The results show considerable economic gains from rebuilding fisheries, with magnitudes varying across fisheries

Designing MPAs for food security in open-access fisheries

Food security remains a principal challenge in the developing tropics where communities rely heavily on marine-based protein. While some improvements in fisheries management have been made in these regions, a large fraction of coastal fisheries remain unmanaged, mismanaged, or use only crude input controls. These quasi-open-access conditions often lead to severe overfishing, depleted stocks, and compromised food security. A possible fishery management approach in these institution-poor settings is to implement fully protected marine protected areas (MPAs). Although the primary push for MPAs has been to solve the conservation problems that arise from mismanagement, MPAs can also benefit fisheries beyond their borders. The literature has not completely characterized how to design MPAs under diverse ecological and economic conditions when food security is the objective. We integrated four key biological and economic variables (i.e., fish population growth rate, fish mobility, fish price, and fishing cost) as well as an important aspect of reserve design (MPA size) into a general model and determined their combined influence on food security when MPAs are implemented in an open-access setting. We explicitly modeled open-access conditions that account for the behavioral response of fishers to the MPA; this approach is distinct from much of the literature that focuses on assumptions of “scorched earth” (i.e., severe over-fishing), optimized management, or an arbitrarily defined fishing mortality outside the MPA’s boundaries. We found that the MPA size that optimizes catch depends strongly on economic variables. Large MPAs optimize catch for species heavily harvested for their high value and/or low harvesting cost, while small MPAs or no closure are best for species lightly harvested for their low value and high harvesting cost. Contrary to previous theoretical expectations, both high and low mobility species are expected to experience conservation benefits from protection, although, as shown previously, greater conservation benefits are expected for low mobility species. Food security benefits from MPAs can be obtained from species of any mobility. Results deliver both qualitative insights and quantitative guidance for designing MPAs for food security in open-access fisheries

The Grizzly, November 19, 2015

On the Way to the Final Four • Watson Finalists Prepare for Next Steps • U-Imagine Center Offers First Course • Committee Searches for Violence Prevention Educator • International Perspective: Dealing With Graduation Concerns Abroad • Warming Up to the Challenge • Podcast Roars to Life • Preparing for Professional Life • Opinions: It\u27s On Us is Insufficient; Wellness Critics are Ill-Informed • New Era Begins for Women\u27s Basketball • Two Wrestlers Named Preseason All-Americans • Final Four Boundhttps://digitalcommons.ursinus.edu/grizzlynews/1678/thumbnail.jp

Evaluating tradeoffs among ecosystem services to inform marine spatial planning

A central challenge for natural resource management is developing rigorous yet practical approaches for balancing the costs and benefits of diverse human uses of ecosystems. Economic theory has a long history of evaluating tradeoffs in returns from different assets to identify optimal investment strategies. There has been recent progress applying this framework to the delivery of ecosystem services in land use planning. However, despite growing national and international interest in marine spatial planning, we lack parallel frameworks in the marine realm. This paper reviews an ecosystem service tradeoff analysis framework and provides a more comprehensive synthesis for how it can be applied to marine spatial planning and marine ecosystem-based management. A tradeoff analysis approach can reveal inferior management options, demonstrate the benefits of comprehensive planning for multiple, interacting services over managing single services, and identify ‘compatible’ services that provide win-win management options.Keywords: marine spatial planning, efficiency frontier, ecosystem based management, tradeoff analysis, economics, ecosystem service

Greco-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with rucosopasem (GC4711) in the treatment of locally advanced or borderline resectable nonmetastatic pancreatic cancer

Background: While treatment of pancreatic cancer has advanced, survival rates remain low. Stereotactic body radiotherapy (SBRT; high dose per fraction radiation) may exhibit improved clinical outcomes in locally advanced pancreatic cancer but carries potential gastrointestinal toxicity risks. Rucosopasem (GC4711) is one of a class of investigational selective dismutase mimetics that rapidly and specifically converts superoxide to hydrogen peroxide. Studies have shown that normal cells tolerate hydrogen peroxide fluxes better than cancer cells. As radiation response modifiers, dismutase mimetics have the potential to increase tumor control of SBRT without compromising radiation safety. In a pilot phase 1/2 trial in patients with pancreatic cancer, avasopasem, a dismutase mimetic related to rucosopasem, nearly doubled median overall survival in patients receiving SBRT vs placebo plus SBRT. Improvements versus placebo were also observed in local tumor control, time to metastases, and progression-free survival. Altogether, these data support the hypothesis that rucosopasem may improve survival and the benefit-risk ratio of SBRT by improving efficacy without increasing gastrointestinal toxicity. Methods: GRECO-2 is a phase 2, multicenter, randomized, double-blind, placebo-controlled study (NCT04698915) to determine the effect of adding rucosopasem to SBRT on overall survival in patients with borderline resectable or locally advanced, unresectable nonmetastatic pancreatic cancer following initial chemotherapy with a FOLFIRINOX-based regimen or a gemcitabine doublet. Approximately 160 patients will be randomized (approximately 35 sites) to receive rucosopasem 100 mg or placebo via IV infusion over 15 minutes, prior to each SBRT fraction (5 x 10 Gy). Patients judged to be resectable will undergo surgical exploration within 8 weeks after SBRT. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, locoregional control, time to metastasis, surgical resection rate, RO resection rate, best overall response, in-field local response, and safety (acute and late toxicities). Exploratory endpoints include PRO-CTCAE and CA19-9 normalization

Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis

Abstract (provisional) Background Fatigue is one of the most commonly reported and debilitating symptoms of multiple sclerosis (MS); approximately two-thirds of people with MS consider it to be one of their three most troubling symptoms. It may limit or prevent participation in everyday activities, work, leisure, and social pursuits, reduce psychological well-being and is one of the key precipitants of early retirement. Energy effectiveness approaches have been shown to be effective in reducing MS-fatigue, increasing self-efficacy and improving quality of life. Cognitive behavioural approaches have been found to be effective for managing fatigue in other conditions, such as chronic fatigue syndrome, and more recently, in MS. The aim of this pragmatic trial is to evaluate the clinical and cost-effectiveness of a recently developed group-based fatigue management intervention (that blends cognitive behavioural and energy effectiveness approaches) compared with current local practice. Methods This is a multi-centre parallel arm block-randomised controlled trial (RCT) of a six session group-based fatigue management intervention, delivered by health professionals, compared with current local practice. 180 consenting adults with a confirmed diagnosis of MS and significant fatigue levels, recruited via secondary/primary care or newsletters/websites, will be randomised to receive the fatigue management intervention or current local practice. An economic evaluation will be undertaken alongside the trial. Primary outcomes are fatigue severity, self-efficacy and disease-specific quality of life. Secondary outcomes include fatigue impact, general quality of life, mood, activity patterns, and cost-effectiveness. Outcomes in those receiving the fatigue management intervention will be measured 1 week prior to, and 1, 4, and 12 months after the intervention (and at equivalent times in those receiving current local practice). A qualitative component will examine what aspects of the fatigue management intervention participants found helpful/unhelpful and barriers to change. Discussion This trial is the fourth stage of a research programme that has followed the Medical Research Council guidance for developing and evaluating complex interventions. What makes the intervention unique is that it blends cognitive behavioural and energy effectiveness approaches. A potential strength of the intervention is that it could be integrated into existing service delivery models as it has been designed to be delivered by staff already working with people with MS. Service users will be involved throughout this research. Trial registration: Current Controlled Trials ISRCTN7651747

Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes

SummarySomatic mutations in cancer are more frequent in heterochromatic and late-replicating regions of the genome. We report that regional disparities in mutation density are virtually abolished within transcriptionally silent genomic regions of cutaneous squamous cell carcinomas (cSCCs) arising in an XPC−/− background. XPC−/− cells lack global genome nucleotide excision repair (GG-NER), thus establishing differential access of DNA repair machinery within chromatin-rich regions of the genome as the primary cause for the regional disparity. Strikingly, we find that increasing levels of transcription reduce mutation prevalence on both strands of gene bodies embedded within H3K9me3-dense regions, and only to those levels observed in H3K9me3-sparse regions, also in an XPC-dependent manner. Therefore, transcription appears to reduce mutation prevalence specifically by relieving the constraints imposed by chromatin structure on DNA repair. We model this relationship among transcription, chromatin state, and DNA repair, revealing a new, personalized determinant of cancer risk

Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla

Background: Pancreatic cancer, including cancer of the ampulla of Vater and bile duct, is very aggressive and has a poor five year survival rate; improved methods of patient stratification are required. Methods: We assessed the expression of calpain-1, calpain-2 and calpastatin in two patient cohorts using immunohistochemistry on tissue microarrays. The first cohort was composed of 68 pancreatic adenocarcinomas and the second cohort was composed of 120 cancers of the bile duct and ampulla. Results: In bile duct and ampullary carcinomas an association was observed between cytoplasmic calpastatin expression and patient age (P = 0.036), and between nuclear calpastatin expression and increased tumour stage (P = 0.026) and the presence of vascular invasion (P = 0.043). In pancreatic cancer, high calpain-2 expression was significantly associated with improved overall survival (P = 0.036), which remained significant in multivariate Cox-regression analysis (hazard ratio = 0.342; 95% confidence interva l = 0.157-0.741; P = 0.007). In cancers of the bile duct and ampulla, low cytoplasmic expression of calpastatin was significantly associated with poor overall survival (P = 0.012), which remained significant in multivariate Cox-regression analysis (hazard ratio = 0.595; 95% confidence interval = 0.365-0.968; P = 0.037). Conclusion: The results suggest that calpain-2 and calpastatin expression is important in pancreatic cancers, influencing disease progression. The findings of this study warrant a larger follow-up study. Keywords: Calpain, Calpastatin, Pancreas, Ampulla, Bile duct, Cance

Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant

IDH1 mutation is the earliest genetic alteration in low-grade gliomas (LGGs), but its role in tumor recurrence is unclear. Mutant IDH1 drives overproduction of the oncometabolite d-2-hydroxyglutarate (2HG) and a CpG island (CGI) hypermethylation phenotype (G-CIMP). To investigate the role of mutant IDH1 at recurrence, we performed a longitudinal analysis of 50 IDH1 mutant LGGs. We discovered six cases with copy number alterations (CNAs) at the IDH1 locus at recurrence. Deletion or amplification of IDH1 was followed by clonal expansion and recurrence at a higher grade. Successful cultures derived from IDH1 mutant, but not IDH1 wild type, gliomas systematically deleted IDH1 in vitro and in vivo, further suggestive of selection against the heterozygous mutant state as tumors progress. Tumors and cultures with IDH1 CNA had decreased 2HG, maintenance of G-CIMP, and DNA methylation reprogramming outside CGI. Thus, while IDH1 mutation initiates gliomagenesis, in some patients mutant IDH1 and 2HG are not required for later clonal expansions

Clinical characteristics associated with the prescribing of SSRI medication in adolescents with major unipolar depression.

Unipolar major depressions (MD) emerge markedly during adolescence. National Institute for Health and Care Excellence (NICE) UK recommends psychological therapies, with accompanying selective serotonin reuptake inhibitors (SSRIs) prescribed in severe cases only. Here, we seek to determine the extent and rationale of SSRI prescribing in adolescent MD before entering a randomised clinical trial. SSRI prescribing, together with their clinical characteristics was determined in 465 adolescent patients with MD prior to receiving a standardised psychological therapy as part of the Improving mood with psychoanalytic and cognitive therapies (IMPACT) clinical trial. Overall, 88 (19 %) had been prescribed antidepressants prior to psychological treatment. The clinical correlates varied by gender: respectively, depression severity in boys and self-harming behaviours in girls. Prescribing also differed between clinical research centres. Medical practitioners consider severity of depression in boys as an indicator for antidepressant prescribing. Self-injury in girls appears to be utilised as a prescribing aid which is inconsistent with past and current revised UK NICE guidelines.RCT Study supported by a grant to IMG (Chief Investigator) from the NIHR-HTA (trial number ISRCTN83033550, grant number 06/05/01).This is the author accepted manuscript. It is currently under an indefinite embargo pending publication by Springer